The effects of levodopa on balance and gait function in people with Parkinson's disease (PD) is controversial. This study compared the relative responsiveness to L-dopa on six domains of balance and gait: postural sway in stance; gait pace; dynamic stability; gait initiation; arm swing; and turning in people with mild and severe PD, with and without dyskinesia. We studied 104 subjects with idiopathic PD (H & Y II [n 5 52] and III-IV [n 5 52]) and 64 age-matched controls. Subjects performed a mobility task in the practical off state and on L-dopa: standing quietly for 30 seconds, initiating gait, walking 7 meters, and turning 180 degrees. Thirty-four measures of mobility were computed from inertial sensors. Standardized response means were used to determine relative responsiveness to L-dopa. The largest improvements with L-dopa were found for arm swing and pace-related gait measures.
Gait and balance disturbances are common and important clinical manifestations of idiopathic Parkinson's disease (PD). Nevertheless, the effects of dopamine replacement therapy (DRT) on gait and balance is unclear. Fragmented knowledge on balance or gait derives mostly from laboratory studies looking at single aspects of gait or balance on and off levodopa. Dopa-responsive characteristics of gait have been widely described as stride length, gait speed, and double support time variability. 1 In contrast, cadence and other temporal characteristics of gait may be dopa resistant. 1 The effect of dopamine replacement on static balance remains controversial; sway area during quiet standing has been reported to both increase and decrease after L-dopa intake. 2, 3 This discrepancy and others might be explained by differences in disease severity between studies. Other important measures, such as anticipatory postural adjustments (APA) before step initiation, arm swing, and turning while walking, have received scant attention. 4, 5 One reason for the uncertainty about the effects of L-dopa on balance and gait is that balance and gait Relevant conflicts of interest/financial disclosures: Oregon Health & Science University (OHSU) and Dr. Horak have a significant financial interest in APDM, a company that may have a commercial interest in the results of this research and technology. This potential institutional and individual conflict has been reviewed and managed by OHSU. Full financial disclosures and author roles may be found in the online version of this article.
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are often considered to be one function. However, physiological and imaging studies provide evidence for separate supraspinal locomotor and postural control networks in animals and humans. 6 Therefore, to understand the effects of L-dopa on the more global function of mobility, it is essential to study the effects of L-dopa over a wide spectrum of postural and locomotor tasks, ranging from control of postural sway during quiet standing and steady gait, to movement that requires modulation of stereotypical gait, such as gait initiation and turning. A second reason for the uncertainty about the effects of L-dopa on balance and gait is that the effects of L-dopa may change with disease progression and presence of dyskinesia. Thus, a large sample of subjects with a wide range of disease severities is required to understand the effects of L-dopa on balance and gait in parkinsonism. The aim of this study was to compare the effects of L-dopa across a variety of balance and gait parameters in a large number of people with idiopathic PD and varying disease severity using objective measures from body-worn inertial sensors. We hypothesized that L-dopa responsiveness would differ for different aspects of gait and balance and that disease severity and dyskinesia would influence L-dopa responsiveness.
Patients and Methods

Participants
We recruited 104 participants with a clinical diagnosis of idiopathic PD 7 and undergoing treatment with L-dopa and a group of 64 age-matched healthy control subjects (Table 1 ). All subjects with PD and controls were free of musculoskeletal and other neurological impairments that could affect gait and balance. Potential PD subjects for this study were approached through advertisement in the clinic, referral through clinicians, and recruitment from our database of volunteers. Healthy control subjects were recruited from spouses and caregivers of the participants and our database of healthy volunteers. The protocol was approved by the Oregon Health & Science University (OHSU) Institutional Review Board. All participants gave their informed consent according to the Declaration of Helsinki.
Procedure
The subjects with PD were tested in the morning in their practical off state, that is, at least 12 hours after their last intake of antiparkinsonian medications. 8 The ISAW consisted of standing quietly for 30 seconds, followed by a verbal instruction to initiate gait with the most involved leg or dominant leg for control subjects, walk 7 meters, turn 180 degrees after crossing a line on the ground, and return to the initial starting position (Fig. 1) . During quiet standing, subjects were asked to keep their arms at their sides and look straight ahead. A template was used to achieve consistent foot placement with 10 cm between heels and a 30-degree outward rotation of the feet. 10 based on video recordings of the clinical assessments on and off. Rigidity ratings from an UPDRS-trained researcher's scoring were used to complete the otherwise blinded video assessment. The Postural Instability and Gait Difficulty (PIGD) four-item subscore was calculated from the Motor UPDRS (arising from a chair, standing posture, gait, and postural stability/pull test). L-dopa equivalent daily dose (LEDD) was determined for each of the subjects with PD. 11 Subjects also completed the Activitiesspecific Balance Confidence (ABC) Scale 12 and the Mobility section of the Parkinson's Disease Questionnaire (PDQ-39). 13 Finally, subjects reported the number of falls in the previous 12 months.
Equipment
Subjects wore six inertial sensors on both wrists, both ankles, the sternum and at the fifth lumbar level attached by elastic Velcro straps. Inertial sensors used were either MTX (Xsens; https://www.xsens.com) or Opal (APDM Inc; http://apdm.com). The sensors have similar characteristics; interchangeability of systems was confirmed though concurrent evaluation (data unpublished). APDM Mobility Lab software was used to extract all gait and balance parameters. 8 
Outcome Measures
Analysis focused on 34 reliable and valid measures of mobility (Fig. 1 ). [14] [15] [16] [17] Based on the results of a Postural sway: Sway-related measures included root mean square (RMS; i.e., dispersion) of sway, mean velocity, centroidal frequency, frequency dispersion, and normalized jerk (i.e., smoothness of sway) in AP and ML direction. Initiation of gait: APAs preceding stepping were characterized by APA duration, APA latency, APA peak trunk acceleration in AP and ML direction, RoM first step, and duration of first step. Gait-pace: Measures included gait cycle time, cadence, stride velocity, stride length, and RoM leg (as approximation of step length). Gait-arm and trunk movement: Arm movement during straight-ahead walking comprised arm peak velocity, arm swing RoM of the most affected arm, and asymmetry arm swing RoM. Trunk movement was described as average RoM of the trunk in the frontal, sagittal, and horizontal plane. Gait-dynamic stability: The gait phases double support time, stance time, and swing time are given as percent of gait cycle. Turning: Performance of turning is measured as peak angular velocity of the trunk, turning duration, mean step time, and number of steps needed for completion of a 180-degree turn.
factor analysis (in preparation), metrics were categorized into independent domains that were assumed to rely upon different neural networks. 18, 19 Metrics were scaled to body size, where appropriate. For a detailed description of the individual metrics and their calculation, see (Appendix 1: Nomenclature). 17, 20 
Statistical Analysis
The median value for each metric was extracted from the three ISAW trials in the on and in the off states. Responsiveness of the different postural control and gait measures to L-dopa is expressed as the standardized response mean (SRM). The SRM was calculated as the mean change between on and off divided by the standard deviation (SD) of the change. Responsiveness to L-dopa is given as improvement or worsening with respect to healthy control subjects. An SRM value of 0.20 represents a small, 0.50 a moderate, and 0.80 a large responsiveness.
To investigate the effect of disease severity and Ldopa on balance and gait, repeated-measures analyses of variance (ANOVAs) were performed. Subjects with PD were divided into two severity groups based on their H & Y stage. PD was considered mild with H & Y I to II (i.e., no clinical signs of postural instability) and severe with H & Y III to IV in the off state. PD subjects were also divided into those with a dyskinesia score 5 0 and > 0 based on the Dyskinesia Rating Scale. If criteria for normality of data distribution (Kolmogorov-Smirnov's test) were not met, data were logarithmically transformed. One-way ANOVAs were used to determine whether subjects with PD performed differently from control subjects. The chisquare test was used to compare history of falls between subjects with and without dyskinesia. Correlation analyses were performed using Spearman's rank correlation. Statistical significance was set to P < 0.05.
Results
Sixty-four healthy control subjects (age, 65.4 6 6.0 years) and 104 subjects with PD (age, 66.5 6 6.1 years) were tested. Subjects with PD were categorized as either mild (H & Y II; n 5 52) or severe (H & Y III-IV; n 5 52). Mean duration of disease was shorter in subjects with mild PD (7.2 6 3.9 years) than subjects with more severe PD (10.4 6 6.8 years). Subjects with mild PD scored 32.8 6 10.5 and subjects with severe PD scored 38.8 6 11.9 on the Motor UPDRS in the off state (Table 1) .
L-dopa Improved but Did Not Normalize Gait
For the group of subjects with PD as a whole, Ldopa induced the largest improvements (SRM > 0.5) in pace-related gait metrics (stride velocity, stride length, and lower leg range of motion [RoM leg]), as well as the arm swing RoM, and arm peak velocity during gait (Figs. 2 and 3 ). Yet, even in these most responsive measures, subjects with PD during their on state were never within an SD of control subject values (Appendix 2). Smaller effects (SRM 5 0.2-0.5) of L-dopa included increasing the size of APAs during step initiation and improving turning measures.
L-dopa Worsened Balance
Unlike the improvement observed in many gait metrics, L-dopa worsened postural sway-sway dispersion (RMS) and sway velocity increased in the on state, indicating that subjects with PD were less stable when on than when off L-dopa.
No changes with L-dopa were found in dynamic stability metrics (double support time and swing time) during gait (SRM < 0.2). These temporal gait metrics were also not different between subjects with PD and control subjects (Appendix 2).
SRM analysis revealed that Motor UPDRS scores and PIGD subscores were large to moderately responsive to L-dopa (Motor UPDRS: SRM 5 0.81; PIGD: SRM 5 0.52; Fig. 2 ).
Effects of Severity of PD on Measures of Balance and Gait and Their Response to Ldopa
Most metrics of pace, arm and trunk movement, turning, APA, and sway showed differences between control subjects and subjects with PD in either the on or off state. However, none of the dynamic stability measures during gait detected differences between people with PD and healthy control subjects. As expected, subjects with advanced PD were significantly more impaired than subjects with mild PD in: stride velocity (Fig. 3A) ; stride length (Fig. 3B) ; leg RoM; size of the APA in mediolateral (ML ; Fig. 3C ); and sway in ML direction ( Fig. 3D ; sway RMS ML, sway mean velocity ML, and centroidal frequency ML). Arm swing velocity and range of the most affected arm (Fig. 3E) were not significantly different between subjects with advanced versus mild PD, and arm swing improved equally in both groups. There was an interaction between severity of disease and responsiveness to Ldopa on three measures. Only in the more severely affected subjects postural sway was increased (RMS ML in Fig. 3D ), turning duration was shortened (Fig.  3F) , and mean step time during turning decreased (Appendix 2; Interaction: L-dopa 3 Severity).
L-dopa-Induced Dyskinesia Increases Postural Instability
Of the 104 subjects with PD, 40 exhibited dyskinesia during testing. Subjects with dyskinesia had slightly lower on state Motor UPDRS scores (25.3 6 10.6)
than subjects without dyskinesia (32.3 6 12.1). Dyskinetic subjects had a larger L-dopa-induced improvement of Motor UPDRS (8.5 6 8.1) than subjects without dyskinesia (4.3 6 6.4). The effects of L-dopa on balance and gait were influenced by the presence of dyskinesia. Subjects without dyskinesia showed no changes in speed of turning or in postural sway with L-dopa. In contrast, subjects with L-dopa-induced dyskinesia had an exaggerated arm swing (P 5 0.001; Fig. 4A ) and turned significantly faster in the on than off state (P 5 0.004; Fig.  4B ). Dyskinetic subjects swayed significantly more during stance in the on, compared to off, state (P < 0.001; Fig. 4C ). The L-dopa-induced increase in postural sway correlated with a decrease in turning duration (r 5 20.286; P < 0.005). Consistent with the larger postural sway in dyskinetic subjects, the percentage of subjects with recurrent falls over the past year (2) tended to be higher in the group with dyskinesia (27.5%) than in the group without dyskinesia (12.5%; v 2 [1; N 5 104] 5 3.709; P 5 0.054).
Discussion Spectrum of L-dopa Responsiveness
This is the first study to compare L-dopa responsiveness on balance, gait, and postural transitions (gait initiation and turning) in the same large cohort of patients with idiopathic PD. We found a wide spectrum of L-dopa-induced changes in mobility measures that ranged from improvement to worsening.
The mixed responsiveness of balance and gait to Ldopa has two immediate implications. First, it indicates that gait and balance are not a single function; instead, there are distinct, as well as overlapping, multiple neural circuits involved in control of balance and gait, with varying sensitivity to L-dopa. Thus, various aspects of gait and balance must be evaluated individually. Successful and safe mobility will be a consequence of the integration of these and other aspects of gait and balance.
Second, the lack of improvement or worsening of some measures with L-dopa supports the emerging view of PD as a multisystem failure including degeneration in cholinergic and norepinephrine circuits that may be important for control of balance and gait. 21 Furthermore, recent imaging studies have shown abnormalities in cortical, cerebellar, and brainstem nodes of the locomotor networks, as well as in the basal ganglia, in people with PD. 6, 22 Thus, pharmacological treatment of balance and gait in PD may need to consider manipulating neurotransmitters of cortical and brainstem circuits, rather than just focusing on nigrostriatal DRT.
Improvement of Gait
The measures most improved by L-dopa were arm swing range/velocity and gait velocity/stride length, indicating that these metrics would be good to monitor the on and off fluctuations of parkinsonism related to medication cycles. Our results are consistent with previous laboratory studies, showing improvement of pacerelated gait measures, such as gait velocity and stride length with L-dopa. 1, 23 However, it is important to note that even in the on state, these very L-dopa-responsive measures did not come within an SD of these measures in control subjects. In addition, step initiation, cadence, and turning were improved to a lesser extent by L-dopa. This is in accord with a PET study that demonstrated that balance and gait measures of the UPDRS (PIGD) signs were not correlated with dopamine concentration in the putamen, although higher dopamine concentrations were associated with improvement of rigidity and bradykinesia. 24 In contrast, the temporal aspects of gait that determine the amount of time two feet, versus one foot, are on the ground, a sign of dynamic stability, were not impaired in patients with PD and did not change with L-dopa.
FIG. 3.
Effect of L-dopa and severity of PD on (A) stride velocity, (B) stride length, (C) APA peak ML, (D) sway RMS ML, (E) arm swing RoM ML, and (F) turning duration. Black line and gray area represent healthy controls (mean 6 standard error).
C U R T Z E E T A L
Worsening of Balance
In the current study, L-dopa increased ML and anteroposterior (AP) postural sway velocity and variability during quiet standing in subjects with H & Y stages III to IV. Postural sway is a well-recognized measure of fall risk in general and also in PD. 25 The deleterious effects of L-dopa on postural sway are not an isolated example of exacerbating postural stability in PD. We previously have shown that L-dopa worsens postural responses to surface displacements. 26 In contrast to postural sway, balance control during gait (i.e., double support time) was not impaired by PD or changed by L-dopa. The difference between static and dynamic balance control suggests that these domains of balance depend upon different neural circuits.
Effect of Dyskinesia
Splitting our PD cohort into two groups on the basis of dyskinesia observed during the testing produced two groups with similar disease severity on UPDRS motor scores. However, the increased postural sway with Ldopa was confined to the subject group with dyskinesia. Dyskinesia appeared to drive the increase in sway during quiet standing given that the extent and frequency of postural sway was related to their clinical dyskinesia ratings. This was not a surprise because we previously found that postural sway velocity and its variability were a sensitive measure of dyskinesia during quiet stance.
27
Dyskinesia increases postural sway by adding higherfrequency, involuntary movements to normal, lowfrequency postural sway. 20 If dyskinesia is not associated with stabilizing anticipatory postural adjustments, these involuntary movements would also increase postural instability. 28 Indeed, dyskinesia was associated with a history of more falls in the previous year in our dyskinetic subjects than the nondyskinetic subjects. Because our dyskinetic group did not have more severe disease, as judged by the Motor UPDRS, than those without dyskinesia, our results suggest that dyskinesia itself contributes to postural instability that could lead to falls. That is, dyskinesia is not simply an indication of more severe disease. An association between dyskinesia and falls has been suggested by other epidemiological studies. [29] [30] [31] In addition to increasing postural sway, L-dopa increased turning speed, which may also increase the risk of falls. Other investigators have shown that subjects with PD turn "en bloc" with a narrow base of support, rather than leading with the eyes and head, regardless of severity of disease or L-dopa state. 5 Thus, the sensorimotor strategy for dynamic balance during turning does not appear to be dopa sensitive, although we found that speed of turning is dopa sensitive. However, because turning speed was increased only in the dyskinetic subjects and related to increased postural sway, it may be that increased turning speed is a product of dyskinesia and not just a direct effect of L-dopa.
As with turning, arm swing is also faster in patients with dyskinesia and becomes exaggerated with L-dopa in some dyskinetic patients. Exaggerated arm swing may be a sign of excessive motor disinhibition without improvement in motor coordination or postural control. This trade-off between speeding up gait, but increasing risk for falls, by impairing postural control is also true for DBS in people with PD. Objective Balance and Gait Measures
Instrumented measures, such as from body-worn, inertial sensors, provide scalable measures of gait and balance dysfunction. Slowness of turning, step initiation, postural sway, and reduced arm swing are important measures of PD that are difficult to assess clinically, much less quantify. These objective measures of balance and gait separated the healthy control subjects from subjects with parkinsonism and more severe subjects with PD from milder subjects. Observations from other studies suggest that inertial sensors may be effective for early disease detection, 34 monitoring disease progression, 35 predicting mobility impairment and falls, 36 and, as shown in this study, measuring response to interventions.
Limitations
This large, observational study has several limitations. The measures of gait did not include variability in gait (too short gait path) nor width of steps, both features that may relate to dynamic stability. A second drawback was studying the subjects in the same order of off, and then on, making sequence effects or fatigue a possible confounder. A third limitation is that the patient and control subgroups were very different in sex ratio, with more males in the patient group. However, females, who generally have lower gait speed, stride length, and so on, than males, predominated in the control group should reduce, rather than enhance, differences in gait characteristics between the control and PD groups. Furthermore, normalizations were applied to correct for potential differences, that is, stride velocity and stride length were scaled to subjects' height. 37 
Conclusion
L-dopa is a double-edged sword for treating mobility dysfunction in people with PD. When on, subjects with PD walked and turned more quickly, but became less stable during quiet standing and probably turning. Dyskinesia, rather than disease severity, accounted for these negative effects of L-dopa.
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